GB Patent

GB9930882D0 — GLP-2 formulations

Assigned to NPS Allelix Corp Canada · Expires 2000-02-23 · 26y expired

What this patent protects

The invention is directed to formulations of GLP-2 peptides and analogs thereof exhibiting superior stability following storage and/or exposure to elevated temperatures. The GLP-2 compositions comprise a GLP-2 peptide or an analog thereof, a phosphate buffer, L-histidine, and man…

USPTO Abstract

The invention is directed to formulations of GLP-2 peptides and analogs thereof exhibiting superior stability following storage and/or exposure to elevated temperatures. The GLP-2 compositions comprise a GLP-2 peptide or an analog thereof, a phosphate buffer, L-histidine, and mannitol.

Drugs covered by this patent

Patent Metadata

Patent number
GB9930882D0
Jurisdiction
GB
Classification
—
Expires
2000-02-23
Drug substance claim
No
Drug product claim
No
Assignee
NPS Allelix Corp Canada
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.